Merck & Co.
AWARDS
NEWS
Shares of Autolus were up more than 12% this morning after it forged an exclusive licensing agreement with Moderna to develop new messenger RNA therapeutics for cancer.
Kaiser Permanente has reportedly filed a lawsuit against drug maker Merck for allegedly allowing a “pay-for-delay” scheme that cost the former millions of dollars.
While modern-day science has provided the world with highly effective vaccines to fight the COVID-19 pandemic, researchers have had less luck finding effective treatment options for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Merck’s Keytruda won FDA approval for the treatment of patients with high-risk, early-stage triple-negative breast cancer. The approval marked the 30th for Keytruda.
The Cambridge-based company is targeting the DNA Damage Response (DDR) pathway to attack various cancers.
It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more.
JOBS
IN THE PRESS